Alcyone Therapeutics Opens, Focus on Gene Therapy for Rett Syndrome

Alcyone Therapeutics Opens, Focus on Gene Therapy for Rett Syndrome

296537

Alcyone Therapeutics Opens, Focus on Gene Therapy for Rett Syndrome

Alcyone Therapeutics, a new company focused on developing gene therapies for disorders that affect the nervous system, announced its official launch. One of its lead candidates, ACTX-101, is an investigational gene therapy for Rett syndrome now in preclinical testing with a goal of bringing into clinical trials in patients “Our mission at Alcyone Therapeutics is to provide life-changing therapies for children and their families impacted by severe neurological conditions,” PJ Anand, founder, president, and CEO of…

You must be logged in to read/download the full post.